WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018017896) PYRIDINE SULFONAMIDES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/017896    International Application No.:    PCT/US2017/043173
Publication Date: 25.01.2018 International Filing Date: 20.07.2017
IPC:
C07D 413/12 (2006.01), C07D 413/14 (2006.01), C07D 213/75 (2006.01), C07D 401/12 (2006.01), C07D 417/12 (2006.01), A61P 25/00 (2006.01)
Applicants: AMGEN INC. [US/US]; One Amgen Center Drive Thousand Oaks, California 91320 (US)
Inventors: WEISS, Matthew; (US).
BUTLER, John R.; (US).
MILGRAM, Benjamin Charles; (US).
RESCOURIO, Gwenaella; (US).
BOEZIO, Alessandro; (US).
SPARLING, Brian Andrew; (US).
LA, Daniel; (US)
Agent: LEMOINE, Elsa D.; (US)
Priority Data:
62/364,437 20.07.2016 US
Title (EN) PYRIDINE SULFONAMIDES
(FR) SULFONAMIDES DE PYRIDINE
Abstract: front page image
(EN)The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
(FR)La présente invention concerne des composés de Formule (I), tel que défini dans la spécification, ou leurs sels pharmaceutiquement acceptés, qui sont des inhibiteurs de canaux sodiques sensibles au voltage, en particulier Nav 1.7. Les composés sont utiles pour le traitement de maladies pouvant être traitées par inhibition des canaux sodiques telles que des troubles de la douleur, la toux ou les démangeaisons. L'invention concerne également des compositions pharmaceutiques contenant les composés de la présente invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)